Voruciclib is an orally active, selective cyclin-dependent kinase (CDK) inhibitor. It effectively inhibits CDK9, a key regulator of MCL-1 transcription. In various diffuse large B-cell lymphoma (DLBCL) models, Voruciclib suppresses MCL-1 expression. This compound is significant in PROTAC development due to its ability to selectively inhibit CDKs and modulate transcriptional regulation. Reagent-grade; for laboratory research purposes only.
Products > Antibody Drug Conjugates (ADC), Oncology API > Oncology API
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.
日本语
한국어
Français
Deutsch
España
Türkiye